Herein, we report the updated PFS, OS, ORR, 2‐year survival rate, and safety data (additional 17‐month follow‐up for a median follow‐up duration of 20.2 months) of 298 patients with NSCLC and high PD‐L1 expression, who received MONO or COMB as a first‐line treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.